Analysis of Antibody Drug Conjugates
23 Dec 2017
As biopharmaceutical organizations explore the use of Antibody Drug Conjugates (ADC) as a class of cancer therapies, significant challenges are found in analyzing their complex, heterogeneous structures. The determination of drug-to-antibody ratios (DAR) and sites of conjugation presents unique analytical challenges that can be addressed with Waters' fit-for-purpose UPLC, QTof MS, and informatics solutions.
About the company
Waters
Waters Corporation, the premium brand in the analytical instruments industry since 1958, creates business advantages for laboratory-dependent organizations by delivering practical and sustainable scientific innovation to enable significant advancements in such areas as: healthcare delivery, environmental management, food safety, chemical materials analysis, and water quality worldwide. Waters helps customers make profound discoveries, optimize laboratory operations, deliver product performance, and ensure regulatory compliance by providing a connected portfolio of separations and analytical science, mass spectrometry, laboratory informatics, as well as thermal analysis products.
